Publications
] "Comparing genome editing technologies." Genetic Engineering & Biotechnology News 34, no. 5 (2014): 1, 32-34.
"Correction of Dystrophin Expression in Cells From Duchenne Muscular Dystrophy Patients Through Genomic Excision of Exon 51 by Zinc Finger Nucleases." Molecular Therapy 23, no. 3 (2015): 523-532.
"Correction of dystrophin expression in cells from Duchenne muscular dystrophy patients through genomic excision of exon 51 by zinc finger nucleases." Molecular Therapy : the Journal of the American Society of Gene Therapy 23, no. 3 (2015): 523-532.
"CRISPR Clocks: The Times They Are a-Changin'." The Crispr Journal 4, no. 2 (2021): 160-163.
"CRISPR technology for gene therapy." Nature Medicine 20, no. 5 (2014): 476-477.
"CRISPR-based methods for high-throughput annotation of regulatory DNA." Current Opinion in Biotechnology 52 (2018): 32-41.
"CRISPR/Cas9 Editing of Murine Induced Pluripotent Stem Cells for Engineering Inflammation-Resistant Tissues." Arthritis & Rheumatology 69, no. 5 (2017): 1111-1121.
"CRISPR-Cas9 epigenome editing enables high-throughput screening for functional regulatory elements in the human genome." Nat Biotechnol 35, no. 6 (2017): 561-568.
"A CRISPR/Cas9-based system for reprogramming cell lineage specification." Stem Cell Reports 3, no. 6 (2014): 940-947.
"Cross-species evolution of a highly potent AAV variant for therapeutic gene transfer and genome editing." Nature Communications 13, no. 1 (2022).
"Design, Assembly, and Characterization of TALE-Based Transcriptional Activators and Repressors." Methods in Molecular Biology (Clifton, N.J.) 1338 (2016): 71-88.
"The Development of TALE Nucleases for Biotechnology." Methods in Molecular Biology (Clifton, N.J.) 1338 (2016): 27-42.
"Differential effects of toll-like receptor stimulation on mRNA-driven myogenic conversion of human and mouse fibroblasts." Biochemical and Biophysical Research Communications 478, no. 3 (2016): 1484-1490.
"Directed evolution of recombinase specificity by split gene reassembly." Nucleic Acids Research 38, no. 12 (2010): 4198-4206.
"Editing the epigenome: technologies for programmable transcription and epigenetic modulation." Nature Methods 13, no. 2 (2016): 127-137.
"Editorial Overview: Synthetic biology and biomedical engineering." Current Opinion in Biomedical Engineering 4 (2017): vi - vii.
"Enabling functional genomics with genome engineering." Genome Research 25, no. 10 (2015): 1442-1455.
"Engineered bioactive molecules." 5 (2011): 131-145.
"An Engineered Optogenetic Switch for Spatiotemporal Control of Gene Expression, Cell Differentiation, and Tissue Morphogenesis." Acs Synthetic Biology 6, no. 11 (2017): 2003-2013.
"Engineering Delivery Vehicles for Genome Editing." Annual Review of Chemical and Biomolecular Engineering 7 (2016): 637-662.
"Engineering synthetic TALE and CRISPR/Cas9 transcription factors for regulating gene expression." Methods (San Diego, Calif.) 69, no. 2 (2014): 188-197.
"Engineering synthetic TALE and CRISPR/Cas9 transcription factors for regulating gene expression." Methods 69, no. 2 (2014): 188-197.
"Enhanced MyoD-induced transdifferentiation to a myogenic lineage by fusion to a potent transactivation domain." Acs Synthetic Biology 4, no. 6 (2015): 689-699.
"Enhancer Histone Acetylation Modulates Transcriptional Bursting Dynamics of Neuronal Activity-Inducible Genes." Cell Reports 26, no. 5 (2019): 1174-1188.e5.
"Enhancer RNAs predict enhancer-gene regulatory links and are critical for enhancer function in neuronal systems." Nucleic Acids Research 48, no. 17 (2020): 9550-9570.